Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Mallinckrodt
AstraZeneca
Express Scripts
Baxter
Dow
Harvard Business School

Last Updated: May 26, 2022

CLINICAL TRIALS PROFILE FOR ACYCLOVIR


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Acyclovir

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000138 ↗ Herpetic Eye Disease Study (HEDS) I Unknown status National Eye Institute (NEI) Phase 3 1989-05-01 To evaluate the efficacy of topical corticosteroids in treating herpes simplex stromal keratitis in conjunction with topical trifluridine. To evaluate the efficacy of oral acyclovir in treating herpes simplex stromal keratitis in patients receiving concomitant topical corticosteroids and trifluridine. To evaluate the efficacy of oral acyclovir in treating herpes simplex iridocyclitis in conjunction with treatment with topical corticosteroids and trifluridine.
NCT00000139 ↗ Herpetic Eye Disease Study (HEDS) II Completed National Eye Institute (NEI) Phase 3 1992-10-01 To determine whether early treatment (with oral acyclovir) of herpes simplex virus (HSV) ulcerations of the corneal epithelium prevents progression to the blinding complications of stromal keratitis and iridocyclitis. To determine the efficacy of low-dose oral acyclovir in preventing recurrent HSV eye infection in patients with previous episodes of herpetic eye disease. To determine the role of external factors (such as ultraviolet light or corneal trauma) and behavioral factors (such as life stress) on the induction of ocular recurrences of HSV eye infections and disease.
NCT00000635 ↗ Treatment of Acyclovir-Resistant Mucocutaneous Herpes Simplex Disease in Patients With AIDS: Open Label Pilot Study of Topical Trifluridine Completed Glaxo Wellcome N/A 1969-12-31 To determine the safety, effectiveness, and toxicity of topical (local) trifluridine in treating mucocutaneous (at the nasal, oral, vaginal, and anal openings) Herpes simplex virus ( HSV ) disease that has shown resistance to acyclovir in HIV-infected patients. HSV infection in patients with AIDS is often associated with skin sores and frequent recurrences. Treatment with the drug acyclovir results in healing for most patients, but repeated treatment sometimes results in resistance of the virus to acyclovir. Thus, when this happens, other treatments need to be used. Trifluridine is an antiviral drug that is used for the treatment of Herpes infections that occur in the eye. This study attempts to determine if trifluridine is useful for treating HSV sores that have not healed after treatment with acyclovir.
NCT00000635 ↗ Treatment of Acyclovir-Resistant Mucocutaneous Herpes Simplex Disease in Patients With AIDS: Open Label Pilot Study of Topical Trifluridine Completed National Institute of Allergy and Infectious Diseases (NIAID) N/A 1969-12-31 To determine the safety, effectiveness, and toxicity of topical (local) trifluridine in treating mucocutaneous (at the nasal, oral, vaginal, and anal openings) Herpes simplex virus ( HSV ) disease that has shown resistance to acyclovir in HIV-infected patients. HSV infection in patients with AIDS is often associated with skin sores and frequent recurrences. Treatment with the drug acyclovir results in healing for most patients, but repeated treatment sometimes results in resistance of the virus to acyclovir. Thus, when this happens, other treatments need to be used. Trifluridine is an antiviral drug that is used for the treatment of Herpes infections that occur in the eye. This study attempts to determine if trifluridine is useful for treating HSV sores that have not healed after treatment with acyclovir.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Acyclovir

Condition Name

Condition Name for Acyclovir
Intervention Trials
HIV Infections 27
Herpes Simplex 23
Herpes Labialis 9
Genital Herpes 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Acyclovir
Intervention Trials
Herpes Simplex 39
HIV Infections 30
Infections 23
Infection 22
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Acyclovir

Trials by Country

Trials by Country for Acyclovir
Location Trials
United States 364
Canada 11
Israel 5
Poland 4
China 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Acyclovir
Location Trials
California 30
Texas 27
New York 26
Illinois 22
Washington 19
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Acyclovir

Clinical Trial Phase

Clinical Trial Phase for Acyclovir
Clinical Trial Phase Trials
Phase 4 15
Phase 3 29
Phase 2/Phase 3 5
[disabled in preview] 26
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Acyclovir
Clinical Trial Phase Trials
Completed 86
Recruiting 11
Unknown status 9
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Acyclovir

Sponsor Name

Sponsor Name for Acyclovir
Sponsor Trials
National Institute of Allergy and Infectious Diseases (NIAID) 20
University of Washington 9
Glaxo Wellcome 9
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Acyclovir
Sponsor Trials
Other 107
Industry 50
NIH 43
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
McKesson
McKinsey
Colorcon
Baxter
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.